U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ABSOLUTE
Molecular Formula C21H28O5
Molecular Weight 360.444
Optical Activity UNSPECIFIED
Defined Stereocenters 7 / 7
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of PREDNISOLONE

SMILES

C[C@]12C[C@H](O)[C@H]3[C@@H](CCC4=CC(=O)C=C[C@]34C)[C@@H]1CC[C@]2(O)C(=O)CO

InChI

InChIKey=OIGNJSKKLXVSLS-VWUMJDOOSA-N
InChI=1S/C21H28O5/c1-19-7-5-13(23)9-12(19)3-4-14-15-6-8-21(26,17(25)11-22)20(15,2)10-16(24)18(14)19/h5,7,9,14-16,18,22,24,26H,3-4,6,8,10-11H2,1-2H3/t14-,15-,16-,18+,19-,20-,21-/m0/s1

HIDE SMILES / InChI

Molecular Formula C21H28O5
Molecular Weight 360.444
Charge 0
Count
Stereochemistry ABSOLUTE
Additional Stereochemistry
Defined Stereocenters 7 / 7
E/Z Centers 0
Optical Activity UNSPECIFIED

Description

Glucocorticoid, Antiinflammatory agent, Glucocorticoid receptor agonist

CNS Activity

Originator

Approval Year

TargetsConditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Palliative
Sixtysix-20
Primary
Prednisolone
Primary
Prednisolut
Primary
OMNIPRED
Primary
OMNIPRED
Primary
OMNIPRED
Primary
Prednisolone
Primary
Prednisolut
Primary
Prednisolone
Primary
Prednisolone
Primary
Prednisolut
Primary
OMNIPRED
Primary
Prednisolone
Primary
Prednisolone
Primary
Prednisolone
Primary
Prednisolut
Primary
OMNIPRED
Primary
Prednisolut
Primary
Prednisolone
Primary
Prednisolone
PubMed

PubMed

TitleDatePubMed
Intravenous hydrocortisone hemisuccinate and prednisolone hemisuccinate.
1956 Dec
[Pharmacokinetics and pharmacodynamics of prednisolone following extremely high dosage as prednisolone hemisuccinate].
1987 Feb
In vivo effects of orally administered prednisolone on prostaglandin and leucotriene production in ulcerative colitis.
1987 Sep
Role of platelet-activating factor in ulcerative colitis. Enhanced production during active disease and inhibition by sulfasalazine and prednisolone.
1988 Nov
Inhibition of calcineurin activity and protection against cyclosporine A induced cytotoxicity by prednisolone sodium succinate in human peripheral mononuclear cells.
2000 Jun
Comparison of suppressive potency between prednisolone and prednisolone sodium succinate against mitogen-induced blastogenesis of human peripheral blood mononuclear cells in-vitro.
2001 May
Effects of octreotide acetate and amniotic membrane on wound healing in experimental glaucoma surgery.
2003 Sep
Prednisolone oral solution plus inhaled procaterol for acute asthma in children: a double-blind randomized controlled trial.
2007 Sep-Oct
Effects of prednisolone on the systemic release of mediators of cell-mediated cytotoxicity during human endotoxemia.
2008 Apr
"ChilDrive": a technique of combining regional cutaneous hypothermia with iontophoresis for the delivery of drugs to synovial fluid.
2009 Nov
11,20-Dihy-droxy-3-oxopregna-1,4-dien-21-oic acid monohydrate.
2011 Jun 1
Corticosteroids for bacterial keratitis: the Steroids for Corneal Ulcers Trial (SCUT).
2012 Feb
Protective effect of selected calcium channel blockers and prednisolone, a phospholipase-A2 inhibitor, against gentamicin and carbon tetrachloride-induced nephrotoxicity.
2014 Aug
The steroids for corneal ulcers trial (SCUT): secondary 12-month clinical outcomes of a randomized controlled trial.
2014 Feb
Preparation, characterization and evaluation of novel elastic nano-sized niosomes (ethoniosomes) for ocular delivery of prednisolone.
2014 Sep
Patents

Sample Use Guides

In Vivo Use Guide
Two drops topically in the eye(s) four times daily.
Route of Administration: Topical ophthalmic
In Vitro Use Guide
Human polymorphonuclear leukocytes (PMNLs) were incubated for 60 min with 20 microM or 100 microM prednisolone, and stimulated thereafter for 1 min with 10 nM leukotriene B4 (LTB4), 10 nM leukotriene C4 (LTC4), 10 nM leukotriene D4 (LTD4) or 10 microM histamine. PMNLs spontaneously released thromboxane B2 (TXB2) during 60 min incubation, and the rate of formation was significantly reduced in the presence of 20 microM or 100 microM prednisolone. LTB4, LTC4, LTD4, and histamine stimulated the rate of TXB2 production during 1 min incubation to 93-, 49-, 60-, and 55-fold, respectively.
Substance Class Chemical
Created
by admin
on Tue Mar 06 10:59:55 UTC 2018
Edited
by admin
on Tue Mar 06 10:59:55 UTC 2018
Record UNII
9PHQ9Y1OLM
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
PREDNISOLONE
EP   GREEN BOOK   HSDB   INN   MART.   MI   ORANGE BOOK   USP-RS   VANDF   WHO-DD   WHO-IP  
INN  
Official Name English
CHLOROPTIC-P S.O.P. COMPONENT PREDNISOLONE
Common Name English
METI-DERM
Brand Name English
NSC-9120
Code English
NSC-9900
Code English
11.BETA.,17,21-TRIHYDROXYPREGNA-1,4-DIENE-3,20-DIONE.
Common Name English
PRELONE
Brand Name English
PREDNISOLONE [MART.]
Common Name English
PREDNISOLONE COMPONENT OF CHLOROPTIC-P S.O.P.
Common Name English
(+)-PREDNISOLONE
Common Name English
PREDNISOLONE [ORANGE BOOK]
Common Name English
PREDNISOLONE ANHYDROUS
Common Name English
DELTAHYDROCORTISONE
Common Name English
APREDNISLON
Common Name English
PREDNISOLONE [EP]
Common Name English
DELTA-CORTEF
Brand Name English
PREDNISOLONE [JAN]
Common Name English
PREDNISOLONE [HSDB]
Common Name English
PANAFCORTELONE
Common Name English
HYDRORETROCORTINE
Common Name English
PREDNISOLONUM [WHO-IP LATIN]
Common Name English
PREDNISOLONE [INN]
Common Name English
CODELCORTONE
Common Name English
FERNISOLONE-P
Brand Name English
PREDNISOLONE [MI]
Common Name English
PREDNISOLONE [VANDF]
Common Name English
PREDNISOLONE [USP-RS]
Common Name English
PREDNISOLONE [GREEN BOOK]
Common Name English
PREDNISOLONE [WHO-DD]
Common Name English
PREGNA-1,4-DIENE-3,20-DIONE, 11,17,21-TRIHYDROXY-, (11.BETA)-
Common Name English
SUPERCORTISOL
Common Name English
DELTACORTRIL
Brand Name English
PREDNISOLONE [WHO-IP]
Common Name English
METACORTANDRALONE
Common Name English
STERANE
Brand Name English
VETSOLONE
Common Name English
CORTALONE
Brand Name English
Classification Tree Code System Code
WHO-VATC QS03CA02
Created by admin on Tue Mar 06 10:59:55 UTC 2018 , Edited by admin on Tue Mar 06 10:59:55 UTC 2018
WHO-VATC QS01CB02
Created by admin on Tue Mar 06 10:59:55 UTC 2018 , Edited by admin on Tue Mar 06 10:59:55 UTC 2018
WHO-VATC QA01AC54
Created by admin on Tue Mar 06 10:59:55 UTC 2018 , Edited by admin on Tue Mar 06 10:59:55 UTC 2018
NDF-RT N0000175576
Created by admin on Tue Mar 06 10:59:55 UTC 2018 , Edited by admin on Tue Mar 06 10:59:55 UTC 2018
WHO-ATC S01CA02
Created by admin on Tue Mar 06 10:59:55 UTC 2018 , Edited by admin on Tue Mar 06 10:59:55 UTC 2018
WHO-ATC D07CA03
Created by admin on Tue Mar 06 10:59:55 UTC 2018 , Edited by admin on Tue Mar 06 10:59:55 UTC 2018
WHO-ATC C05AA04
Created by admin on Tue Mar 06 10:59:55 UTC 2018 , Edited by admin on Tue Mar 06 10:59:55 UTC 2018
WHO-ATC S01CB02
Created by admin on Tue Mar 06 10:59:55 UTC 2018 , Edited by admin on Tue Mar 06 10:59:55 UTC 2018
WHO-ATC A01AC54
Created by admin on Tue Mar 06 10:59:55 UTC 2018 , Edited by admin on Tue Mar 06 10:59:55 UTC 2018
WHO-ATC S02CA01
Created by admin on Tue Mar 06 10:59:55 UTC 2018 , Edited by admin on Tue Mar 06 10:59:55 UTC 2018
WHO-VATC QC05AA04
Created by admin on Tue Mar 06 10:59:55 UTC 2018 , Edited by admin on Tue Mar 06 10:59:55 UTC 2018
CFR 21 CFR 520.1880
Created by admin on Tue Mar 06 10:59:55 UTC 2018 , Edited by admin on Tue Mar 06 10:59:55 UTC 2018
NDF-RT N0000175450
Created by admin on Tue Mar 06 10:59:55 UTC 2018 , Edited by admin on Tue Mar 06 10:59:55 UTC 2018
CFR 21 CFR 520.2604
Created by admin on Tue Mar 06 10:59:55 UTC 2018 , Edited by admin on Tue Mar 06 10:59:55 UTC 2018
WHO-ESSENTIAL MEDICINES LIST 03
Created by admin on Tue Mar 06 10:59:55 UTC 2018 , Edited by admin on Tue Mar 06 10:59:55 UTC 2018
WHO-VATC QD07XA02
Created by admin on Tue Mar 06 10:59:55 UTC 2018 , Edited by admin on Tue Mar 06 10:59:55 UTC 2018
WHO-VATC QH02AB56
Created by admin on Tue Mar 06 10:59:55 UTC 2018 , Edited by admin on Tue Mar 06 10:59:55 UTC 2018
WHO-VATC QS02BA03
Created by admin on Tue Mar 06 10:59:55 UTC 2018 , Edited by admin on Tue Mar 06 10:59:55 UTC 2018
CFR 21 CFR 524.1484K
Created by admin on Tue Mar 06 10:59:55 UTC 2018 , Edited by admin on Tue Mar 06 10:59:55 UTC 2018
WHO-ATC S01BB02
Created by admin on Tue Mar 06 10:59:55 UTC 2018 , Edited by admin on Tue Mar 06 10:59:55 UTC 2018
CFR 21 CFR 520.2345H
Created by admin on Tue Mar 06 10:59:55 UTC 2018 , Edited by admin on Tue Mar 06 10:59:55 UTC 2018
CFR 21 CFR 524.1484F
Created by admin on Tue Mar 06 10:59:55 UTC 2018 , Edited by admin on Tue Mar 06 10:59:55 UTC 2018
WHO-ATC A07EA01
Created by admin on Tue Mar 06 10:59:55 UTC 2018 , Edited by admin on Tue Mar 06 10:59:55 UTC 2018
WHO-VATC QD07CA03
Created by admin on Tue Mar 06 10:59:55 UTC 2018 , Edited by admin on Tue Mar 06 10:59:55 UTC 2018
WHO-ATC V03AB05
Created by admin on Tue Mar 06 10:59:55 UTC 2018 , Edited by admin on Tue Mar 06 10:59:55 UTC 2018
WHO-VATC QS01CA02
Created by admin on Tue Mar 06 10:59:55 UTC 2018 , Edited by admin on Tue Mar 06 10:59:55 UTC 2018
WHO-ATC S03BA02
Created by admin on Tue Mar 06 10:59:55 UTC 2018 , Edited by admin on Tue Mar 06 10:59:55 UTC 2018
WHO-ATC S01BA04
Created by admin on Tue Mar 06 10:59:55 UTC 2018 , Edited by admin on Tue Mar 06 10:59:55 UTC 2018
WHO-VATC QD07BA01
Created by admin on Tue Mar 06 10:59:55 UTC 2018 , Edited by admin on Tue Mar 06 10:59:55 UTC 2018
CFR 21 CFR 524.1445
Created by admin on Tue Mar 06 10:59:55 UTC 2018 , Edited by admin on Tue Mar 06 10:59:55 UTC 2018
WHO-ATC R01AD52
Created by admin on Tue Mar 06 10:59:55 UTC 2018 , Edited by admin on Tue Mar 06 10:59:55 UTC 2018
WHO-ATC H02AB06
Created by admin on Tue Mar 06 10:59:55 UTC 2018 , Edited by admin on Tue Mar 06 10:59:55 UTC 2018
WHO-VATC QS03BA02
Created by admin on Tue Mar 06 10:59:55 UTC 2018 , Edited by admin on Tue Mar 06 10:59:55 UTC 2018
WHO-VATC QS01BA04
Created by admin on Tue Mar 06 10:59:55 UTC 2018 , Edited by admin on Tue Mar 06 10:59:55 UTC 2018
WHO-ATC S02BA03
Created by admin on Tue Mar 06 10:59:55 UTC 2018 , Edited by admin on Tue Mar 06 10:59:55 UTC 2018
WHO-ATC R01AD02
Created by admin on Tue Mar 06 10:59:55 UTC 2018 , Edited by admin on Tue Mar 06 10:59:55 UTC 2018
WHO-ATC D07AA03
Created by admin on Tue Mar 06 10:59:55 UTC 2018 , Edited by admin on Tue Mar 06 10:59:55 UTC 2018
WHO-ATC D07BA01
Created by admin on Tue Mar 06 10:59:55 UTC 2018 , Edited by admin on Tue Mar 06 10:59:55 UTC 2018
WHO-VATC QR01AD52
Created by admin on Tue Mar 06 10:59:55 UTC 2018 , Edited by admin on Tue Mar 06 10:59:55 UTC 2018
WHO-ESSENTIAL MEDICINES LIST 21.2
Created by admin on Tue Mar 06 10:59:55 UTC 2018 , Edited by admin on Tue Mar 06 10:59:55 UTC 2018
WHO-VATC QS02CA01
Created by admin on Tue Mar 06 10:59:55 UTC 2018 , Edited by admin on Tue Mar 06 10:59:55 UTC 2018
WHO-ESSENTIAL MEDICINES LIST 8.3
Created by admin on Tue Mar 06 10:59:55 UTC 2018 , Edited by admin on Tue Mar 06 10:59:55 UTC 2018
WHO-VATC QR01AD02
Created by admin on Tue Mar 06 10:59:55 UTC 2018 , Edited by admin on Tue Mar 06 10:59:55 UTC 2018
WHO-VATC QD07AA03
Created by admin on Tue Mar 06 10:59:55 UTC 2018 , Edited by admin on Tue Mar 06 10:59:55 UTC 2018
WHO-ATC S03CA02
Created by admin on Tue Mar 06 10:59:55 UTC 2018 , Edited by admin on Tue Mar 06 10:59:55 UTC 2018
WHO-VATC QV03AB05
Created by admin on Tue Mar 06 10:59:55 UTC 2018 , Edited by admin on Tue Mar 06 10:59:55 UTC 2018
WHO-VATC QH02AB06
Created by admin on Tue Mar 06 10:59:55 UTC 2018 , Edited by admin on Tue Mar 06 10:59:55 UTC 2018
CFR 21 CFR 520.2605
Created by admin on Tue Mar 06 10:59:55 UTC 2018 , Edited by admin on Tue Mar 06 10:59:55 UTC 2018
WHO-ATC D07XA02
Created by admin on Tue Mar 06 10:59:55 UTC 2018 , Edited by admin on Tue Mar 06 10:59:55 UTC 2018
WHO-VATC QA07EA01
Created by admin on Tue Mar 06 10:59:55 UTC 2018 , Edited by admin on Tue Mar 06 10:59:55 UTC 2018
LIVERTOX 794
Created by admin on Tue Mar 06 10:59:55 UTC 2018 , Edited by admin on Tue Mar 06 10:59:55 UTC 2018
CFR 21 CFR 522.1885
Created by admin on Tue Mar 06 10:59:55 UTC 2018 , Edited by admin on Tue Mar 06 10:59:55 UTC 2018
CFR 21 CFR 524.1484J
Created by admin on Tue Mar 06 10:59:55 UTC 2018 , Edited by admin on Tue Mar 06 10:59:55 UTC 2018
WHO-VATC QS01BB02
Created by admin on Tue Mar 06 10:59:55 UTC 2018 , Edited by admin on Tue Mar 06 10:59:55 UTC 2018
Code System Code Type Description
MERCK INDEX
M9111
Created by admin on Tue Mar 06 10:59:55 UTC 2018 , Edited by admin on Tue Mar 06 10:59:55 UTC 2018
PRIMARY Merck Index
LactMed
50-24-8
Created by admin on Tue Mar 06 10:59:55 UTC 2018 , Edited by admin on Tue Mar 06 10:59:55 UTC 2018
PRIMARY
WIKIPEDIA
PREDNISOLONE
Created by admin on Tue Mar 06 10:59:55 UTC 2018 , Edited by admin on Tue Mar 06 10:59:55 UTC 2018
PRIMARY
PUBCHEM
5755
Created by admin on Tue Mar 06 10:59:55 UTC 2018 , Edited by admin on Tue Mar 06 10:59:55 UTC 2018
PRIMARY SWITZERF
EVMPD
SUB10018MIG
Created by admin on Tue Mar 06 10:59:55 UTC 2018 , Edited by admin on Tue Mar 06 10:59:55 UTC 2018
PRIMARY
WHO INTERNATIONAL PHARMACOPEIA
PREDNISOLONE
Created by admin on Tue Mar 06 10:59:55 UTC 2018 , Edited by admin on Tue Mar 06 10:59:55 UTC 2018
PRIMARY Description: A white or almost white, crystalline powder; odourless. Solubility. Soluble in 1300 parts of water and in 30 parts of dehydrated ethanol R; soluble in methanol R and dioxan R. Category: Adrenocortical steroid. Storage: Prednisolone should be kept in a tightly closed container, protected from light. Additional information: Prednisolone is hygroscopic; it has a melting temperature of about 230?C with decomposition. Definition: Prednisolone contains not less than 97.0% and not more than 102.0% of C21H28O5, calculated with reference to thedried substance.
RXCUI
8638
Created by admin on Tue Mar 06 10:59:55 UTC 2018 , Edited by admin on Tue Mar 06 10:59:55 UTC 2018
PRIMARY RxNorm
NCI_THESAURUS
C769
Created by admin on Tue Mar 06 10:59:55 UTC 2018 , Edited by admin on Tue Mar 06 10:59:55 UTC 2018
PRIMARY
EPA CompTox
50-24-8
Created by admin on Tue Mar 06 10:59:55 UTC 2018 , Edited by admin on Tue Mar 06 10:59:55 UTC 2018
PRIMARY
HSDB
50-24-8
Created by admin on Tue Mar 06 10:59:55 UTC 2018 , Edited by admin on Tue Mar 06 10:59:55 UTC 2018
PRIMARY
DRUG BANK
DB00860
Created by admin on Tue Mar 06 10:59:55 UTC 2018 , Edited by admin on Tue Mar 06 10:59:55 UTC 2018
PRIMARY
INN
535
Created by admin on Tue Mar 06 10:59:55 UTC 2018 , Edited by admin on Tue Mar 06 10:59:55 UTC 2018
PRIMARY
EMA VETERINARY ASSESSMENT REPORTS
EQUISOLON (AUTHORISED)
Created by admin on Tue Mar 06 10:59:55 UTC 2018 , Edited by admin on Tue Mar 06 10:59:55 UTC 2018
PRIMARY HORSES
ChEMBL
CHEMBL131
Created by admin on Tue Mar 06 10:59:55 UTC 2018 , Edited by admin on Tue Mar 06 10:59:55 UTC 2018
PRIMARY
CAS
50-24-8
Created by admin on Tue Mar 06 10:59:55 UTC 2018 , Edited by admin on Tue Mar 06 10:59:55 UTC 2018
PRIMARY
IUPHAR
2866
Created by admin on Tue Mar 06 10:59:55 UTC 2018 , Edited by admin on Tue Mar 06 10:59:55 UTC 2018
PRIMARY
MESH
D011239
Created by admin on Tue Mar 06 10:59:55 UTC 2018 , Edited by admin on Tue Mar 06 10:59:55 UTC 2018
PRIMARY
ECHA (EC/EINECS)
200-021-7
Created by admin on Tue Mar 06 10:59:55 UTC 2018 , Edited by admin on Tue Mar 06 10:59:55 UTC 2018
PRIMARY
Related Record Type Details
TARGET -> AGONIST
BINDER -> LIGAND
BINDING
SALT/SOLVATE -> PARENT
BINDER -> LIGAND
BINDING LARGELY TO ALBUMIN; DOSAGE SHOULD BE REDUCED IN HYPOALBUMINANEMIA
BINDING
Related Record Type Details
PRODRUG -> METABOLITE ACTIVE
Related Record Type Details
ACTIVE MOIETY